AU2017351756B2 - Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders - Google Patents

Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders Download PDF

Info

Publication number
AU2017351756B2
AU2017351756B2 AU2017351756A AU2017351756A AU2017351756B2 AU 2017351756 B2 AU2017351756 B2 AU 2017351756B2 AU 2017351756 A AU2017351756 A AU 2017351756A AU 2017351756 A AU2017351756 A AU 2017351756A AU 2017351756 B2 AU2017351756 B2 AU 2017351756B2
Authority
AU
Australia
Prior art keywords
compound
formula
ethyl
benzimidazole
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017351756A
Other languages
English (en)
Other versions
AU2017351756A1 (en
Inventor
Hatylas FELYPE ZANETI DE AZEVEDO
Valter Freire Torres Russo
Elisa Mannochio De Souza Russo
Alessandra MASCARELLO
Cristiano RUCH WERNECK GUIMARÃES
Renata WATANABE DA COSTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ache Laboratorios Farmaceuticos SA
Original Assignee
Ache Laboratorios Farmaceuticos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos SA filed Critical Ache Laboratorios Farmaceuticos SA
Publication of AU2017351756A1 publication Critical patent/AU2017351756A1/en
Application granted granted Critical
Publication of AU2017351756B2 publication Critical patent/AU2017351756B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017351756A 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders Active AU2017351756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRBR1020160248140 2016-10-24
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (2)

Publication Number Publication Date
AU2017351756A1 AU2017351756A1 (en) 2019-05-09
AU2017351756B2 true AU2017351756B2 (en) 2022-01-27

Family

ID=62023150

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017351756A Active AU2017351756B2 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Country Status (21)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN110088092B (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CA (1) CA3042040A1 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES3013994T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20191046A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG10202009001TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PT3433256T (pt) 2016-10-24 2019-10-31 Astrazeneca Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento do cancro
KR102246668B1 (ko) 2017-01-30 2021-04-29 아스트라제네카 아베 에스트로겐 수용체 조절인자
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
EP0788795B1 (en) * 1994-06-10 2002-11-13 Nauchno-Issledovatelsky Institut Farmakologii Akademii Meditsinskikh Nauk Pharmacologically active 2-mercaptobenzimidazole derivatives
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
AU763963B2 (en) 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
WO2005080334A1 (ja) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
JP2010503654A (ja) * 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
RU2401831C2 (ru) 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use

Also Published As

Publication number Publication date
EP3741760C0 (en) 2024-12-04
ECSP19032963A (es) 2019-05-31
EP3529234A4 (en) 2020-03-11
BR102016024814A2 (pt) 2018-05-08
ES3013994T3 (en) 2025-04-16
KR102594251B1 (ko) 2023-10-25
MX392990B (es) 2025-03-24
SG11201903113TA (en) 2019-05-30
EP3741760A1 (en) 2020-11-25
PE20191046A1 (es) 2019-08-06
EP3529234A1 (en) 2019-08-28
UY40644A (es) 2024-02-29
AR109467A1 (es) 2018-12-12
US10781182B2 (en) 2020-09-22
MX2019004782A (es) 2019-10-09
KR20190066023A (ko) 2019-06-12
CN110088092B (zh) 2022-10-04
UY37334A (es) 2018-04-30
US20190270711A1 (en) 2019-09-05
JP2019537624A (ja) 2019-12-26
SG10202009001TA (en) 2020-10-29
ES2970546T3 (es) 2024-05-29
PT3529234T (pt) 2024-02-01
BR112019008197A2 (pt) 2019-07-16
CA3042040A1 (en) 2018-05-03
JP7194683B2 (ja) 2022-12-22
CN110088092A (zh) 2019-08-02
EP3529234B1 (en) 2023-11-29
CO2019004756A2 (es) 2019-05-21
FI3529234T3 (fi) 2023-12-28
EP3741760B1 (en) 2024-12-04
CL2019001105A1 (es) 2019-09-06
US11091445B2 (en) 2021-08-17
PE20250558A1 (es) 2025-02-24
AU2017351756A1 (en) 2019-05-09
WO2018076090A1 (en) 2018-05-03
CN115181108A (zh) 2022-10-14
DK3529234T3 (da) 2024-02-05
US20200277265A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
AU2017351756B2 (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
US20070293554A1 (en) Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
JP2022511269A (ja) シャペロン介在性オートファジー調節剤として有用な化合物
EP2065039A1 (en) Selective inhibition of Polo-like kinase 1
HK40081925A (en) Compounds, and preparation process, pharmaceutical composition and use thereof
N’Ait Ousidi et al. Diastereoselective synthesis of new Thiazolyl-Indazole derivatives from R-carvone: A combined experimental and theoretical study
CN107304188A (zh) 一种氘代激酶选择性抑制剂及其应用
Kallinen et al. Synthesis and preclinical evaluation of fluorinated 5-azaindoles as CB2 PET radioligands
HK40011198B (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
HK40011198A (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
CN118791500B (zh) 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用
BR112019008197B1 (pt) Composto, processo de obtenção do composto, composição farmacêutica e uso do composto
JP2025537145A (ja) Par2の低分子調節物質及びその使用
EP3620160A1 (en) Liphagal analog and multi-targeted kinase inhibitor containing liphagal or analog thereof
EP4545533A1 (en) Spiro compound and use
CN107304201A (zh) 一种氘代激酶选择性抑制剂
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
CN120230029A (zh) 整合素α4β7拮抗剂化合物及其制备方法与应用
WO2019173506A1 (en) Cyclopentaimidazolones for the treatment of cancer
JP2000247968A (ja) ポリアリール抗腫瘍剤
SK9092003A3 (en) 1,1-Dioxo-2H-1,2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)